

MAGE-A1 (h): 293T Lysate: sc-176623

BACKGROUND

The melanoma-associated antigen (MAGE) family consists of a number of antigens recognized by cytotoxic T lymphocytes. The MAGE genes were initially isolated from different kinds of tumors, and based on their virtually exclusive tumor-specific expression in adult tissues, they have been used as targets for cancer immunotherapy. MAGE genes encode for tumor-rejection antigens and are expressed in tumors of different histologic types, but not in normal tissues, with the exception of testis and placenta. Although a large number of MAGE genes have now been identified and extensively studied in tumors of various origin, their function in normal cells remains unknown.

REFERENCES

- Okami, J., Dohno, K., Sakon, M., Iwao, K., Yamada, T., Yamamoto, H., Fujiwara, Y., Nagano, H., Umeshita, K., Matsuura, N., Nakamori, S. and Monden, M. 2000. Genetic detection for micrometastasis in lymph node of biliary tract carcinoma. *Clin. Cancer Res.* 6: 2326-2332.
- Granelli, P., Siardi, C., Zennaro, F., Cattaneo, M., Malferrari, G., Buffa, R., Fociani, P., Fregoni, F., De Ruberto, F., Fichera, G., Peracchia, A. and Biunno, I. 2000. Melanoma antigen genes 1 and 2 are differentially expressed in human gastric and cardiac carcinomas. *Scand. J. Gastroenterol.* 35: 528-533.
- Klein, C., Bueler, H. and Mulligan, R.C. 2000. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. *J. Exp. Med.* 191: 1699-1708.
- Busam, K.J., Iversen, K., Berwick, M., Spagnoli, G.C., Old, L.J. and Jungbluth, A.A. 2000. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters. *Mod. Pathol.* 13: 459-465.
- Kobayashi, Y., Higashi, T., Nouse, K., Nakatsukasa, H., Ishizaki, M., Kaneyoshi, T., Toshikuni, N., Kariyama, K., Nakayama, E. and Tsuji, T. 2000. Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma. *J. Hepatol.* 32: 612-617.
- Luiten, R. and van der Bruggen, P. 2000. A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes. *Tissue Antigens* 55: 149-152.
- Osterlund, C., Töhhönen, V., Forslund, K.O. and Nordqvist, K. 2000. MAGE-B4, a novel melanoma antigen (MAGE) gene specifically expressed during germ cell differentiation. *Cancer Res.* 60: 1054- 1061.

CHROMOSOMAL LOCATION

Genetic locus: MAGEA1 (human) mapping to Xq28.

PRODUCT

MAGE-A1 (h): 293T Lysate represents a lysate of human MAGE-A1 transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

APPLICATIONS

MAGE-A1 (h): 293T Lysate is suitable as a Western Blotting positive control for human reactive MAGE-A1 antibodies. Recommended use: 10-20 µl per lane.


Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

MAGE (5G152): sc-71536 is recommended as a positive control antibody for Western Blot analysis of enhanced human MAGE-A1 expression in MAGE-A1 transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).


RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended:
1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

DATA



MAGE (5G152): sc-71536. Western blot analysis of MAGE-A1 expression in non-transfected: sc-117752 (A) and human MAGE-A1 transfected: sc-176623 (B) 293T whole cell lysates.



MAGE-A (6C1): sc-20034. Western blot analysis of MAGE-A1 expression in non-transfected: sc-117752 (A) and human MAGE-A1 transfected: sc-176623 (B) 293T whole cell lysates.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.